Atopic dermatitis (AD) is a chronic, inflammatory, and pruritic skin disease. Recently, upadacitinib, a selective JAK-1 inhibitor, has been incorporated for AD treatment. Real clinical practice studies are scarce, with only a few case series. [1][2][3][4] In this multicenter retrospective study, upadacitinib was evaluated in a series of patients with moderate to severe AD included in premarketing programs in Spain. Data collected included age, disease duration, comorbidities, and previous treatments. Disease severity was measured by SCORing Atopic Dermatitis (SCORAD), Eczema Area and Severity Index (EASI), investigator's global assessment (IGA) body surface area, Dermatology Life Quality Index, Peak Pruritus Numerical Rating Scale (PP-NRS), and blood test parameters (eosinophil count, total immunoglobulin E, hemoglobin, low-density lipoprotein and high-density lipoprotein cholesterol, triglycerides, creatine phosphokinase, gamma-glutamyl transferase, glutamic oxaloacetic transaminase and glutamic pyruvic transaminase levels) at the baseline visit and at weeks 4, 16, 24, and 52.Twenty-two patients were included in the study. Demographic and baseline characteristics are shown in Table 1. Approved 15-or 30-mg daily doses were prescribed at the discretion of the prescribing physician, with no changes during the follow-up period. All values improved rapidly from week 4 of follow-up (Figs. 1A-D). Mean EASI decreased to 4.4 ± 5.2 (84.2% improvement), SCORAD to 18.5 ± 22.8 (69.2% improvement), and PP-NRS to 2.4 ± 2.9 (70.0% improvement) at week 52 ( P < 0.0001 for